Closed · RFA-MH-15-800 · CFDA 93.242;93.865 · Discretionary
Consortium on Biomarker and Outcome Measures of Social Impairment for Use in Clinical Trials in Autism Spectrum Disorder (U19)
Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.
- up to $5.3M
- Award range
- Closed
- Status
- December 10, 2014
- Close date
- 1
- Expected awards
The verdict
Consortium on Biomarker and Outcome Measures of Social Impairment for Use in Clinical Trials in Autism Spectrum Disorder (U19) is a closed discretionary listing from National Institutes of Health that offered Up to $5,250,000 across 1 expected award. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 12,419 other opportunities from National Institutes of Health.
- up to $5.3M
- award range
- Closed
- application status
- 1
- expected award
- 93.242;93.865
- CFDA program
Archived opportunity record
Consortium on Biomarker and Outcome Measures… is closed (last close December 10, 2014). Check the agency catalog for replacement NOFOs. National Institutes of Health still indexes 12,419 other opportunities here.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
Closed December 10, 2014
Est. Total Funding
$3,525,000
Expected Awards
1
Instrument
Cooperative Agreement
Description
The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for the Consortium on Biomarkers and Outcome Measures of Social Impairment in Autism Spectrum Disorder (ASD) in order to generate objective tools for use in clinical trials of behavioral or pharmacologic interventions. The FOA will support a Consortium project to conduct a multi-site study to assess a well-justified set of standardized lab-based measures of domains of social impairment and biological measures (resting state and task-based EEG as well as eye tracking measures) that show promise in school age individuals with ASD at baseline, 6 and 24 week time points. The intent of the FOA is to qualify a set of measures that can be used as stratification biomarkers and/or as sensitive and reliable objective measures of social impairment in ASD clinical trials. A key goal of the Consortium projectis to provide a community resource for broad sharing of all data generated including processed/analyzed data, with rapid and timely deposition of data into the National Database for Autism Research (NDAR). All data generated in this project are expected to be deposited in NDAR and will be accessible for use by all qualified investigators. In addition, blood (DNA) samples are expected to be deposited in the NIMH Repository and Genomics Resource for future research use.The Consortium project will assess the following: (1) whether lab-based measures of specific domains of social impairment in ASD are more sensitive indicators of clinical status compared to commonly used clinician and caregiver assessments of social impairment for their potential use as outcome measures in clinical trials; (2) whether eye-tracking, electrophysiological (EEG) paradigms, or a combination of the two, have potential utility as stratification biomarkers and/or as sensitive and reliable measures of change in ASD clinical trials; (3) the relationship (correlation) of lab-based measures of domains of social impairment to eye tracking or EEG (resting state and task-based) paradigms; and (4) the relationship (correlation) of lab-based measures of domains of social impairment to commonly used clinician and caregiver assessments of social impairment. In addition, the FOA includes a resource aim for the collection of blood (DNA) samples from all subjects, including the parents of ASD subjects, for future genomic analyses.
Wide-open applicant board · 15 Grants.gov doors
Consortium on Biomarker and Outcome Measures… prints 15 distinct Grants.gov eligibility doors (State governments; County governments; City or township governments; Special district governments; +11 more). Filter fit before reading award size as demand — most applicant classes appear on the row. The extract does not mark applicant cost-sharing as required. Instrument: Cooperative Agreement. Funding-activity codes span Health · Income Security and Social Services (HL;ISS). This eligibility-code string dominates the National Institutes of Health book (9,741 peers, 78% of 12,420).
- Code 00
- State governments
- Code 01
- County governments
- Code 02
- City or township governments
- Code 04
- Special district governments
- Code 05
- Independent school districts
- Code 06
- Public / state-controlled institutions of higher education
- Code 07
- Federally recognized tribal governments
- Code 08
- Public / Indian housing authorities
- Code 11
- Native American tribal organizations (other than Federally recognized tribal governments)
- Code 12
- Nonprofits with 501(c)(3) status (other than IHEs)
- Code 13
- Nonprofits without 501(c)(3) status (other than IHEs)
- Code 20
- Private institutions of higher education
- Code 22
- For-profit organizations other than small businesses
- Code 23
- Small businesses
- Code 25
- Others (see official listing text)
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
More from National Institutes of Health
Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)
Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)
Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
What to do next
Consortium on Biomarker and Outcome Measures… is closed; use the parent program and agency catalog for the next funding cycle.
- Browse open federal opportunities in the same category when this listing is closed. Open opportunities
- Look up CFDA 93.242;93.865 across all indexed listings before you commit to this opportunity alone. Eligibility finder
- National Institutes of Health lists 12,419 other indexed opportunities on PlainGrants. Agency catalog
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |